December 23, 2012Future Cardiology
Using Cardiac Biomarkers and Treating Cardiotoxicity in Cancer
Key result
Cardiac troponin elevation during chemotherapy identifies patients at risk for myocardial dysfunction, in whom angiotensin-converting enzyme inhibitors like enalapril improve clinical outcomes.
Population
Cancer patients receiving anticancer treatments at risk for or developing cardiotoxicity and myocardial…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May enable earlier preventive strategies in cardio-oncology; hypothesis-generating and requires prospective validation before practice change.
Key Points
- This research aims to investigate the effectiveness of cardiac biomarkers in predicting cardiotoxicity and improving patient outcomes during cancer treatment.
- Examined cardiac biomarkers for early identification of myocardial dysfunction in cancer patients undergoing treatment.
- Used angiotensin-converting enzyme inhibitors like enalapril to improve outcomes in patients identified as high-risk.
- Evaluated the use of heart failure therapies for patients who develop left ventricular dysfunction.
- Cardiac troponin elevations were identified as important prognostic indicators for myocardial dysfunction.
- Patients treated with enalapril showed improved clinical outcomes compared to those who did not receive it.
- Heart failure therapies were effective for managing left ventricular dysfunction in cancer patients, although underutilized.
Structured PICO
P
Population
Cancer patients receiving anticancer treatments at risk for or developing cardiotoxicity and myocardial dysfunction
I
Intervention
Cardiac biomarker monitoring (cardiac troponin) and cardioprotective therapy (ACE inhibitors such as enalapril, and beta-blockers)
Cardiac troponin monitoring allows for early detection of chemotherapy-induced cardiotoxicity, enabling targeted cardioprotective therapy with ACE inhibitors to improve clinical outcomes before functional impairment occurs.
Cite This Study
Colombo et al. (2012) conducted a review in Cardiotoxicity in cancer. Cardiac biomarkers and cardioprotective therapy was evaluated. Cardiac troponin elevation during chemotherapy identifies patients at risk for myocardial dysfunction, in whom angiotensin-converting enzyme inhibitors like enalapril improve clinical outcomes.